Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.

SELLAS Life Sciences (NASDAQ:SLS) traded higher in the premarket on Tuesday after the New York-based biotech said that a Phase 2 trial that tested its antitumor agent SLS009 (tambiciclib) as part of a ...